Biodefense Market

The Global Biodefense Market size was estimated at USD 18.7 billion in 2025 and is projected to reach USD 39.8 billion by 2035, growing at a CAGR of 7.8% from 2026 to 2035. The market continues to gain strategic relevance as governments, public health agencies, defense institutions, and critical infrastructure operators reposition biological threat preparedness as a permanent component of national security planning. Expansion in surveillance systems, medical countermeasure procurement, pathogen detection infrastructure, and emergency stockpiling frameworks is reshaping procurement cycles across both civilian and military ecosystems.

Market Overview

The Biodefense Market occupies a structurally unique position at the intersection of public health resilience, military preparedness, advanced diagnostics, and strategic national infrastructure protection. Unlike conventional healthcare procurement markets that are primarily volume-driven, biodefense procurement is heavily influenced by threat perception, geopolitical instability, pathogen mutation risk, and continuity-of-government planning. This creates a market structure in which long procurement cycles coexist with urgent emergency-driven purchasing phases, resulting in uneven but highly strategic capital allocation patterns. The market has gradually transitioned from being event-triggered toward becoming an embedded layer of national preparedness architecture, particularly after global disruptions exposed weaknesses in response coordination, supply chain redundancy, and biological surveillance systems.

The strategic relevance of the Biodefense Market extends beyond outbreak mitigation into areas such as border security, food system protection, biosurveillance modernization, and protection of military personnel deployed in high-risk environments. Executive leadership teams monitor this market because procurement decisions often influence broader investments across diagnostics, pharmaceutical manufacturing capacity, laboratory infrastructure, secure logistics, and emergency response technologies. The market also exhibits characteristics of policy-protected demand, where procurement continuity is frequently sustained even during wider economic slowdowns due to national security prioritization. As a result, the sector demonstrates a different investment behavior compared with conventional healthcare equipment markets, with long-term contract visibility often outweighing short-term demand fluctuations.

Key Market Drivers & Industrial Demand Dynamics

The expansion of biological threat preparedness programs remains the primary structural driver supporting the Biodefense Market forecast. Governments increasingly view biodefense capabilities as critical infrastructure rather than discretionary public health expenditure. This shift has accelerated procurement of rapid diagnostic systems, biological agent detection technologies, vaccine stockpiles, and emergency medical countermeasures. The underlying cause is the growing recognition that biological events can disrupt labor productivity, transportation systems, defense readiness, and economic continuity simultaneously. The impact extends beyond healthcare costs into sovereign risk exposure and industrial disruption. Consequently, procurement agencies are prioritizing scalable response systems capable of operating across both military and civilian emergency scenarios.

Another major demand catalyst originates from the modernization of biosurveillance infrastructure. Legacy surveillance systems historically operated through fragmented laboratory reporting mechanisms with limited real-time coordination. However, evolving pathogen mobility patterns, urban population density, and international travel connectivity have increased pressure on governments to establish integrated surveillance architectures capable of rapid signal detection and cross-border intelligence sharing. This transition has strengthened demand for automated detection platforms, genomic sequencing technologies, environmental monitoring systems, and AI-enabled pathogen analytics. For suppliers, the market increasingly rewards integrated platform capabilities rather than isolated products, creating competitive advantages for firms capable of delivering interoperable ecosystems.

The Biodefense Market size is also influenced by sustained procurement from defense agencies focused on force protection. Military biodefense priorities differ materially from civilian preparedness frameworks because operational continuity in hostile or remote environments requires portable, rapid-response, and contamination-resistant technologies. This has elevated procurement of field diagnostics, protective equipment, decontamination systems, and vaccine platforms suitable for accelerated deployment. The strategic consequence is the emergence of dual-use technologies that simultaneously serve military operations, emergency healthcare systems, and critical infrastructure security applications. Such overlap has expanded addressable demand while also increasing regulatory complexity for manufacturers operating across classified and civilian procurement channels.

Domestic manufacturing resilience has emerged as another critical industrial demand dynamic. Governments experienced substantial supply chain vulnerability during periods of global healthcare disruption, particularly in relation to vaccines, reagents, specialized chemicals, and laboratory consumables. As a result, many procurement authorities are reshaping contract structures to prioritize regional manufacturing capacity, strategic reserves, and vertically integrated supply arrangements. The resulting impact is a procurement environment where manufacturing localization increasingly influences contract awards alongside technological capability. Suppliers able to demonstrate production continuity, inventory stability, and rapid scale-up capacity are gaining stronger negotiating leverage in long-term agreements.

Public-private collaboration models are additionally reshaping the commercial structure of the Biodefense Market. Governments increasingly rely on partnerships with biotechnology firms, contract manufacturers, research institutions, and advanced diagnostics providers to accelerate innovation timelines. This approach reduces dependence on purely state-operated research systems while expanding commercialization pathways for emerging technologies. The broader strategic implication is that the market now functions as a hybrid ecosystem combining defense procurement discipline with biotechnology innovation cycles. Investors therefore assess not only product efficacy but also partnership positioning, regulatory relationships, and platform adaptability across multiple threat categories.

Segmentation Analysis

By type, the Biodefense Market is broadly segmented into detection systems, medical countermeasures, decontamination systems, biosurveillance platforms, and personal protective equipment. Detection systems accounted for the largest share of the Biodefense Market size in 2025 due to their foundational role in early threat identification and containment coordination. Governments prioritize these systems because delayed detection amplifies both public health impact and economic disruption. Demand behavior within this segment is heavily influenced by procurement modernization cycles rather than seasonal healthcare demand, creating longer replacement periods but higher contract values. Suppliers operating in detection systems often benefit from elevated switching barriers because interoperability with national laboratory infrastructure and defense communication networks creates institutional dependency once systems are deployed.

Medical countermeasures represent one of the highest strategic value segments due to their direct role in mortality reduction and emergency response stabilization. This category includes vaccines, therapeutics, antitoxins, and emergency pharmaceutical stockpiles. While procurement volumes fluctuate according to perceived threat intensity, governments typically maintain baseline reserve requirements that support recurring demand continuity. Margin structures in this segment remain stronger than in conventional pharmaceutical markets because specialized production requirements, regulatory scrutiny, and emergency authorization capabilities limit supplier participation. However, inventory management complexity and expiration-related replacement cycles introduce cost pressures that procurement agencies continuously attempt to optimize through long-duration framework agreements.

Decontamination systems and personal protective equipment continue to serve essential operational functions across military, healthcare, transportation, and critical infrastructure environments. Although these segments are comparatively lower margin than advanced medical countermeasures, they remain procurement priorities because they directly influence workforce continuity during biological incidents. Demand cycles are particularly sensitive to emergency preparedness audits and regulatory compliance mandates. Buyers increasingly favor modular systems that can be integrated into existing emergency response infrastructure without requiring complete operational redesign. This preference reduces procurement friction while strengthening demand for suppliers capable of offering integrated contamination management ecosystems rather than standalone equipment.

By application, the Biodefense Market is segmented into military defense, public health preparedness, border and transportation security, food and agriculture protection, and research applications. Military defense contributed over one-third of demand in 2025 because armed forces require continuous operational readiness against both conventional and unconventional biological threats. Procurement behavior in this segment is shaped by multi-year strategic defense planning rather than annual healthcare budgeting cycles. The resulting impact is stronger contract visibility and higher technical specification requirements. Suppliers serving this segment must navigate extensive compliance protocols, secure manufacturing requirements, and classified procurement frameworks, all of which raise entry barriers and reinforce supplier concentration.

Public health preparedness applications continue to expand as governments institutionalize emergency response capabilities developed during previous global health crises. Unlike military procurement, public health demand is influenced by political accountability, healthcare infrastructure resilience, and population-scale emergency planning. This segment favors scalable solutions capable of supporting mass testing, vaccination campaigns, and rapid outbreak containment. Procurement agencies also prioritize technologies that can be repurposed across multiple biological threat scenarios, thereby improving utilization efficiency outside emergency periods. As a result, flexible platform technologies are increasingly preferred over single-pathogen solutions.

Border security, transportation protection, and food system monitoring applications represent strategically important growth layers within the Biodefense Market forecast. Governments increasingly recognize that biological threats can emerge through agricultural contamination, cargo movement, migration flows, or transportation network disruption. Demand in these segments is sustained by regulatory monitoring obligations and the need to maintain continuity across trade and logistics systems. Compared with military-focused applications, these segments generally operate with lower procurement budgets but broader deployment footprints. Suppliers therefore compete through scalability, automation efficiency, and low-maintenance operational models.

By end user, the market includes defense agencies, public health authorities, hospitals and emergency response institutions, research laboratories, and critical infrastructure operators. Defense agencies remained the dominant procurement category in 2025 due to their centralized purchasing power, long-term budgeting visibility, and direct integration with national security frameworks. Procurement in this segment often prioritizes survivability, deployment speed, and interoperability with command-and-control systems. Such requirements create high qualification thresholds that protect incumbent suppliers while limiting commoditization risk.

Public health authorities represent a structurally important end-user segment because they coordinate outbreak response, surveillance programs, and national stockpile management. Procurement behavior here is heavily influenced by funding continuity, regulatory compliance obligations, and political risk exposure. Hospitals and emergency response institutions, meanwhile, prioritize rapid deployment capability, workforce protection, and contamination management efficiency. These buyers typically favor solutions that integrate seamlessly into existing emergency workflows, reducing retraining requirements and operational disruption.

Research laboratories and critical infrastructure operators are becoming increasingly relevant as biological risk monitoring expands beyond healthcare environments. Research institutions drive demand for advanced analytical systems, secure containment infrastructure, and genomic monitoring technologies. Critical infrastructure operators, including energy, transportation, and industrial facilities, increasingly invest in biodefense preparedness to reduce operational shutdown risk associated with biological incidents. This diversification of end-user demand broadens the commercial foundation of the Biodefense industry analysis while reducing dependence on purely government-funded emergency procurement cycles.

By technology, the market includes molecular diagnostics, immunoassay systems, genomic sequencing platforms, biosensors, and AI-enabled surveillance analytics. Molecular diagnostics accounted for a material minority of procurement expenditure because they combine relatively fast deployment with strong diagnostic accuracy across diverse pathogen categories. Genomic sequencing technologies are gaining strategic traction due to their role in variant tracking, outbreak attribution, and epidemiological intelligence generation. However, adoption remains partially constrained by infrastructure intensity, specialist workforce requirements, and data integration complexity.

AI-enabled surveillance analytics are emerging as a differentiating layer within advanced biodefense infrastructure. Governments and large institutional buyers increasingly prioritize predictive analytics capabilities capable of identifying abnormal biological activity patterns before large-scale outbreak escalation occurs. This transition is reshaping supplier competition away from hardware-only models toward data integration ecosystems. Suppliers capable of combining diagnostics, surveillance, analytics, and reporting architectures into unified platforms are expected to secure stronger long-term procurement positioning.

Strategic Market Snapshot

The Biodefense Market demonstrates characteristics of a strategically protected industry with moderate cyclicality and relatively strong pricing resilience compared with broader healthcare equipment sectors. Demand volatility primarily emerges from emergency procurement surges rather than traditional consumer demand fluctuations. Because procurement decisions are closely linked to national preparedness mandates, contract continuity often persists despite macroeconomic slowdown conditions. Buyer–supplier dynamics remain uneven across segments, with governments exercising strong purchasing influence in commoditized categories while specialized technology providers retain leverage in advanced diagnostics, genomic analytics, and secure manufacturing capabilities.

Market maturity varies substantially by product category. Protective equipment and basic decontamination systems operate within relatively mature procurement environments characterized by standardized specifications and price competition. Conversely, biosurveillance analytics, genomic intelligence systems, and advanced vaccine platforms remain innovation-driven segments where procurement agencies prioritize capability differentiation over lowest-cost sourcing. This divergence creates a dual-speed market structure in which suppliers balance stable recurring contracts with higher-risk innovation investments.

Value Chain, Cost Structure & Procurement Intelligence

The Biodefense Market relies on a complex value chain involving biotechnology inputs, specialized reagents, secure manufacturing facilities, containment-certified logistics systems, advanced analytical software, and highly regulated distribution networks. Cost structures are particularly sensitive to laboratory-grade materials, energy-intensive manufacturing processes, and regulatory compliance expenditure. Producers operating within vaccine and therapeutic categories face additional cost exposure associated with cold-chain requirements, biosafety containment infrastructure, and validation testing.

Procurement cycles in the Biodefense Market are considerably longer than those observed in conventional healthcare supply chains because purchasing decisions often involve defense ministries, public health agencies, emergency management authorities, and regulatory bodies simultaneously. Multi-year procurement frameworks remain common, especially for strategic stockpiles and surveillance infrastructure. Contract tenure frequently extends beyond standard healthcare procurement windows because governments prioritize continuity of supply and manufacturing assurance. This creates relatively stable revenue visibility for qualified suppliers but also intensifies competitive pressure during tender qualification stages.

Switching friction remains structurally high across advanced biodefense systems. Governments and institutional buyers are generally reluctant to replace incumbent technologies once integrated into national surveillance networks or emergency response protocols due to retraining costs, interoperability risks, and operational disruption concerns. Supplier relationship breakpoints usually emerge during major technology transitions, budget reallocations, or regulatory modernization initiatives. Consequently, suppliers invest heavily in long-term institutional relationships, compliance credibility, and integrated service capabilities rather than purely transactional sales strategies.

Market Restraints & Regulatory Challenges

Despite its strategic importance, the Biodefense Market faces multiple structural constraints that influence procurement pace and supplier profitability. One of the primary challenges involves regulatory complexity across diagnostics, therapeutics, surveillance systems, and cross-border biological materials management. Products often require multilayer approvals spanning healthcare, defense, environmental, and transportation authorities. These compliance burdens extend commercialization timelines and raise development costs, particularly for smaller technology providers attempting to scale internationally.

Budget allocation inconsistency also creates operational uncertainty. Although biological preparedness has gained stronger policy attention, procurement intensity frequently fluctuates according to geopolitical events, public health emergencies, and fiscal priorities. Periods without visible biological threats can reduce political urgency, delaying modernization programs or inventory replacement cycles. This creates uneven revenue realization patterns for suppliers dependent on government procurement concentration.

Another restraint involves the technical complexity associated with maintaining readiness across evolving biological threat profiles. Technologies designed for one category of pathogen may require substantial modification for emerging biological risks, increasing ongoing research and validation expenditure. At the same time, procurement agencies demand increasingly rapid deployment timelines while maintaining strict safety and efficacy standards. This tension between speed and compliance raises operational risk for manufacturers and research organizations.

Market Opportunities & Outlook (2026–2035)

The long-term Biodefense Market forecast remains supported by the institutionalization of biological risk preparedness across both civilian and military infrastructure planning. Rather than viewing biodefense spending as temporary emergency expenditure, governments increasingly treat it as a recurring component of national resilience investment. This transition is expected to support stable procurement demand across surveillance systems, vaccine manufacturing infrastructure, rapid diagnostics, and contamination management technologies.

Commercial opportunities are likely to expand most aggressively in integrated surveillance ecosystems linking genomic sequencing, AI-driven analytics, environmental monitoring, and cross-agency reporting systems. The strategic value of these technologies lies in their ability to reduce detection latency and improve coordinated response efficiency. Suppliers capable of offering interoperable architectures with scalable deployment models are expected to strengthen long-term contract positioning.

Regional opportunity distribution will remain uneven. Mature procurement environments in North America and Europe are expected to prioritize modernization and technological sophistication, while Asia Pacific demand is increasingly shaped by manufacturing localization, healthcare infrastructure expansion, and regional preparedness initiatives. Latin America and the Middle East & Africa are likely to emphasize scalable public health readiness frameworks and essential detection capabilities, particularly in urban population centers and transportation corridors.

Regional & Country-Level Strategic Insights

North America accounted for over one-third of the global Biodefense Market size in 2025 due to established defense procurement systems, advanced biotechnology infrastructure, and sustained government investment in biological threat preparedness. The region maintains strong integration between military research programs, public health agencies, and private-sector biotechnology developers, creating an ecosystem capable of supporting both innovation and large-scale deployment.

Europe continues to prioritize coordinated biosurveillance frameworks, pharmaceutical manufacturing resilience, and cross-border emergency response integration. Regional procurement strategies increasingly emphasize interoperability among public health systems and standardized preparedness protocols. Asia Pacific is emerging as a strategically important growth region due to expanding healthcare infrastructure, domestic biotechnology investment, and heightened focus on pandemic resilience planning. Countries across the region are strengthening laboratory networks, surveillance systems, and vaccine manufacturing capacity to reduce external dependency.

Latin America and the Middle East & Africa remain comparatively underpenetrated but strategically relevant for future preparedness investment. Urbanization pressures, transportation connectivity, and healthcare infrastructure modernization are supporting gradual expansion of surveillance and emergency response procurement. Governments in these regions are increasingly prioritizing scalable and cost-efficient solutions capable of improving preparedness without requiring extensive infrastructure redesign.

Technology, Innovation & Derivative Trends

Technological evolution within the Biodefense Market is increasingly centered on response speed, interoperability, and predictive intelligence generation. Molecular diagnostics continue to advance toward faster turnaround times and portable deployment formats, enabling decentralized testing capabilities across military, border security, and emergency healthcare environments. These improvements are strategically important because response timing directly influences containment efficiency and operational continuity.

AI-driven analytics and genomic surveillance technologies are reshaping how governments and institutions interpret biological risk patterns. Instead of relying solely on reactive laboratory reporting, surveillance systems increasingly incorporate predictive modeling, environmental sampling, and integrated epidemiological intelligence. This transformation supports earlier intervention while reducing dependence on manual reporting structures.

Derivative innovation is also emerging across secure manufacturing, contamination-resistant materials, autonomous monitoring systems, and modular laboratory infrastructure. Sustainability considerations are influencing procurement as buyers evaluate energy efficiency, waste reduction, and long-term operational maintenance requirements. Advanced biodefense systems are therefore evolving beyond emergency response tools into continuously operating resilience infrastructure.

Competitive Landscape Overview

The Biodefense competitive landscape remains moderately consolidated within highly regulated segments while fragmented in emerging technology categories. Established suppliers benefit from regulatory familiarity, secure manufacturing infrastructure, and longstanding procurement relationships with defense and public health agencies. These advantages create substantial entry barriers, particularly for companies lacking validated production capabilities or government contracting experience.

Competition is increasingly shifting from isolated product performance toward integrated solution delivery. Procurement agencies favor suppliers capable of combining diagnostics, surveillance analytics, logistics support, training, and maintenance into unified operational ecosystems. As a result, strategic partnerships, acquisitions, and collaborative development agreements are becoming central competitive tools within the market.

Innovation intensity remains high in biosurveillance analytics, genomic intelligence systems, and rapid-response diagnostic platforms. However, commercial success depends not only on technological differentiation but also on regulatory execution, manufacturing scalability, and procurement alignment. Suppliers capable of balancing innovation agility with institutional reliability are expected to maintain stronger long-term positioning.

Key Players 

• Emergent BioSolutions Inc.
• Bavarian Nordic A/S
• SIGA Technologies Inc.
• Dynavax Technologies Corporation
• Altimmune Inc.
• Elusys Therapeutics Inc.
• Pfizer Inc.
• Moderna Inc.
• BioNTech SE
• AstraZeneca PLC
• GSK plc
• Merck & Co. Inc.
• Johnson & Johnson
• Sanofi S.A.
• CSL Seqirus
• Roche Holding AG
• Fujifilm Holdings Corporation
• Battelle Memorial Institute
• General Dynamics Information Technology Inc.
• Leidos Holdings Inc.

Recent Developments

In March 2026, Emergent BioSolutions secured a contract award valued at approximately USD 54 million from the U.S. Administration for Strategic Preparedness and Response for additional doses of CNJ-016 Vaccinia Immune Globulin Intravenous for smallpox preparedness, alongside new international orders for ACAM2000 smallpox vaccines, reinforcing continued government stockpiling and global biodefense procurement activity.

In February 2026, Emergent BioSolutions reported expanded international penetration plans for its medical countermeasures business following improved operating performance, reflecting increasing commercialization efforts beyond U.S. federal procurement channels and broader biodefense supply diversification.

In late 2025, U.S. biodefense policy discussions increasingly emphasized integration of biotechnology, AI-enabled biosurveillance, domestic manufacturing resilience, and secure biological supply chains within national defense frameworks, influencing procurement priorities and future biodefense infrastructure investments.

In September 2025, Emergent BioSolutions received a USD 17 million BARDA contract modification to supply oral suspension TEMBEXA for smallpox preparedness after FDA approval of manufacturing scale-up, expanding deployment flexibility for vulnerable patient populations and strengthening domestic biodefense supply chain capabilities.

In September 2025, Emergent BioSolutions obtained a USD 30 million BARDA contract modification for procurement of CYFENDUS anthrax vaccine doses, supporting continued expansion of the U.S. anthrax countermeasure stockpile and reinforcing long-term domestic vaccine manufacturing commitments.

In September 2025, the U.S. government expanded procurement of ACAM2000 smallpox and mpox vaccines through a USD 56 million contract modification with Emergent BioSolutions, reflecting heightened emphasis on orthopoxvirus preparedness and sustained strategic national stockpile replenishment.

In August 2025, the U.S. Department of Health and Human Services initiated a wind-down of multiple BARDA-funded mRNA vaccine development activities, signaling a strategic shift toward alternative vaccine platforms and potentially reshaping future biodefense R&D allocation and platform selection.

In July 2025, Emergent BioSolutions secured a USD 51.9 million contract modification award for delivery of CNJ-016 Vaccinia Immune Globulin Intravenous to support U.S. smallpox preparedness efforts, reinforcing sustained investment in medical countermeasure stockpiles.

In June 2025, Emergent BioSolutions received a USD 62.4 million ASPR contract modification for BAT botulism antitoxin supply under an existing 10-year agreement, strengthening long-term biodefense inventory planning and domestic countermeasure availability.

In January 2025, Emergent BioSolutions received a USD 16.7 million BARDA option award to continue development collaboration for Ebanga Ebola treatment, supporting advanced validation and long-term stability activities tied to federal biodefense preparedness programs.

Methodology & Data Credibility

This Biodefense industry analysis is built using a combination of bottom-up market modeling, procurement trend assessment, demand–supply validation, and cross-regional intelligence triangulation. Market sizing frameworks incorporate analysis of procurement contracts, public health infrastructure investment, defense modernization programs, laboratory deployment trends, and biological preparedness expenditure patterns.

Primary research inputs include executive interviews conducted with procurement managers, biodefense program directors, laboratory infrastructure specialists, strategic sourcing executives, emergency preparedness consultants, and biotechnology manufacturing stakeholders. Secondary validation incorporates regulatory filings, policy frameworks, technology deployment trends, and institutional investment patterns across major regions.

Cross-region triangulation methods are used to reconcile disparities between procurement visibility, deployment intensity, and manufacturing capacity. Analytical models further evaluate pricing structures, replacement cycles, inventory management behavior, and technology adoption pathways to support a comprehensive Biodefense Market forecast.

Who Should Read This Report

This report is designed for enterprise decision-makers evaluating strategic exposure to the Biodefense Market and related preparedness infrastructure sectors. CXOs can use the analysis to assess long-term procurement trends, investment priorities, and technology positioning within evolving biological security frameworks. Strategy teams benefit from detailed segmentation intelligence that clarifies demand behavior, buyer priorities, and supplier positioning across end-user categories.

Investors and institutional capital allocators can leverage the report to evaluate structural demand resilience, procurement cyclicality, competitive barriers, and technology transition pathways. Consultants and advisory teams may use the analysis to support market entry planning, procurement strategy development, partnership assessments, and policy alignment initiatives. Product and portfolio managers can further utilize the insights to identify commercialization opportunities, differentiation strategies, and procurement-sensitive innovation priorities.

What This Report Delivers

This report delivers decision-oriented intelligence designed to support strategic planning, investment evaluation, procurement positioning, and competitive assessment across the global Biodefense Market. The analysis goes beyond surface-level categorization by examining the structural forces influencing procurement behavior, technology adoption, regulatory complexity, and supplier leverage.

Readers gain access to integrated insights covering market structure, segmentation dynamics, value chain economics, regional preparedness priorities, and long-term commercialization opportunities. The report is specifically structured to support executive-level decision making by connecting biological threat preparedness trends with operational, financial, and strategic implications across defense, healthcare, and critical infrastructure ecosystems.

Biodefense Market Report Segmentation

By Type

• Detection Systems
• Medical Countermeasures
• Decontamination Systems
• Biosurveillance Platforms
• Personal Protective Equipment

By Application

• Military Defense
• Public Health Preparedness
• Border & Transportation Security
• Food & Agriculture Protection
• Research Applications

By End User

• Defense Agencies
• Public Health Authorities
• Hospitals & Emergency Response Institutions
• Research Laboratories
• Critical Infrastructure Operators

By Region

• North America: United States, Canada
• Europe: Germany, United Kingdom, France, Italy, Spain, Rest of Europe
• Asia Pacific: China, India, Japan, South Korea, Australia, Southeast Asia, Rest of Asia Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa: GCC, South Africa, Rest of Middle East & Africa